Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.

@article{Zhang2014EfficacyAS,
  title={Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.},
  author={Li Zhang and Ping Li and Chang-ying Xing and Jiu-Yang Zhao and Ya-Ni He and Jian-qin Wang and Xiong-fei Wu and Zhang-suo Liu and Ai-ping Zhang and Hong-Li Lin and Xiaoqiang Ding and Ai-ping Yin and Fa-huan Yuan and P. L. Fu and Li Qiang Hao and Li-ning Miao and Ru-juan Xie and Rong Wang and Chun-hua Zhou and Guang-ju Guan and Zhao Hu and Shan Lin and Ming Chih Chang and Miao Zhang and Li-qun He and Chang-Lin Mei and Li Wang and Xiangmei Chen},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={2014},
  volume={64 1},
  pages={57-65}
}
BACKGROUND Abelmoschus manihot, a single medicament of traditional Chinese medicine, has been widely used to treat kidney disease. This is the first randomized controlled clinical trial to assess its efficacy and safety in patients with primary glomerular disease. STUDY DESIGN Prospective, open-label, multicenter, randomized, controlled, clinical trial. SETTING & PARTICIPANTS From May 2010 to October 2011, a total of 417 patients with biopsy-proven primary glomerular disease from 26… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…